Pharmaceuticals News and Research

RSS

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

IPS Research joins SAFE-BioPharma Association

IPS Research Company, a major southwest clinical research investigator site located in Oklahoma City, OK, has joined SAFE-BioPharma Association and taken another step in the process of eliminating paper copies from its operations.

28 May 2010

New study examines internal and external uses of health outcomes data for promotional purposes

Health outcomes data can be an important promotional/commercial tool for the biopharma industry, but approaches differ company to company as the marketplace continues to evolve. A new study by Best Practices, LLC examines internal and external uses of health outcomes data for promotional purposes.

28 May 2010

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of data from its Phase 3 (FAME) clinical trials for Iluvien, the company's investigational intravitreal insert being studied for diabetic macular edema (DME), indicates that patient vision continues to improve significantly over 30 months.

28 May 2010

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

In an effort to meet the rising rates of melanoma head-on, The Wistar Institute today announced the creation of The Wistar Institute Melanoma Research Center. The Center brings together scientists, physicians, the life sciences industry, and melanoma advocates in saving lives by advancing new and better therapies for this deadly disease.

28 May 2010

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.

28 May 2010

WellPoint guidelines may bolster federal 'comparative effectiveness' investments

The health insurer WellPoint has announced guidelines for using comparative effectiveness studies to pit drugs against one another and determine which works best, the Indianapolis Business Journal reports. "Congress has also approved $4.1 billion in the past 15 months to fund comparative-effectiveness studies and a new agency that specializes in them.

28 May 2010

Salix Pharmaceuticals to sell $300 million of 2.75% convertible senior notes due 2015

Salix Pharmaceuticals, Ltd. today announced that it has entered into an agreement to sell $300 million aggregate principal amount of its 2.75% convertible senior notes due 2015. In addition, Salix has granted the underwriters an overallotment option to purchase up to an additional $45 million aggregate principal amount of notes on the same terms and conditions.

28 May 2010

Celsis International updates Drug Master Files with FDA

Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.

28 May 2010

Corvalen M introduced for treatment of fibromyalgia symptoms

Fibromyalgia affects as many as one in 50 Americans, 90 percent of whom are women. Yet, despite its nearly epidemic status, patients still often rely on pharmaceutical options solely for treatment. That's why Bioenergy Life Science, Inc. has introduced Corvalen M, a natural treatment option for fibromyalgia symptoms.

28 May 2010

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Emisphere Technologies, Inc., a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to further extend the maturity date of Emisphere's Convertible Promissory Note to June 4, 2010.

27 May 2010

Salix Pharmaceuticals announces $200 million convertible senior notes offering

Salix Pharmaceuticals, Ltd. today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of its convertible senior notes due 2015 under an automatically effective shelf registration statement on file with the Securities and Exchange Commission. Salix also expects to grant the underwriters an overallotment option to purchase up to an additional $30 million aggregate principal amount of notes on the same terms and conditions.

27 May 2010

SonoSite signs agreement to acquire privately held Visualsonics

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced that it has signed an agreement to acquire privately held Visualsonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology. The aggregate transaction value will be approximately $71 million net of cash and debt.

27 May 2010

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea

BioDelivery Sciences International, Inc. announced that it has entered into a license and supply agreement with Kunwha Pharmaceutical Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of Korea. The agreement results in potential milestone payments to BDSI of up to $1,275,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales.

27 May 2010

Prohibiting cap messages will increase medication errors: Survey

At a meeting today of the United States Pharmacopeia's (USP) Nomenclature Expert Committee, the Consortium for the Advancement of Patient Safety (CAPS) presented results of an independent study producing a landmark three-part report, including a human factors engineering (HFE) analysis, on the relationship between patient safety and printed messages on ferrule and cap overseals used to secure injectable drug vials.

27 May 2010

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

27 May 2010

Blocking the activity of PAT proteins stops cancer cell growth: Scientists

Cancer Research UK-funded scientists have revealed that a set of proteins act as the cell's 'nose' to 'sniff out' molecules which trigger cell growth, according to research published in Oncogene today.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Sanofi-aventis, MIT announce strategic alliance agreement for SABIP

Sanofi-aventis announced today a strategic alliance agreement with the Massachusetts Institute of Technology Center for Biomedical Innovation, which will be known as the sanofi-aventis Biomedical Innovation Program.

27 May 2010

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

Alvine Pharmaceuticals, Inc., a privately held clinical stage biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/inflammatory diseases, today announced that Abbott Biotech Ventures Inc., has joined Alvine's current investors: Interwest Partners, Panorama Capital, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures in the company's Series A Extension financing. The terms of the investment were not disclosed.

27 May 2010

Pharmaceuticals News and Research

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

IPS Research joins SAFE-BioPharma Association

New study examines internal and external uses of health outcomes data for promotional purposes

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

The Wistar Institute Melanoma Research Center launched to develop new therapies for melanoma

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

WellPoint guidelines may bolster federal 'comparative effectiveness' investments

Salix Pharmaceuticals to sell $300 million of 2.75% convertible senior notes due 2015

Celsis International updates Drug Master Files with FDA

Corvalen M introduced for treatment of fibromyalgia symptoms

Emisphere Technologies announces further extension of Convertible Promissory Note maturity date

Salix Pharmaceuticals announces $200 million convertible senior notes offering

SonoSite signs agreement to acquire privately held Visualsonics

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea

Prohibiting cap messages will increase medication errors: Survey

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

Blocking the activity of PAT proteins stops cancer cell growth: Scientists

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Sanofi-aventis, MIT announce strategic alliance agreement for SABIP

Abbott Biotech Ventures invests in Alvine Pharmaceuticals

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence